Podcasts about Pfizer

Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Mario Beauregard, PhD, is a cognitive neuroscientist who studies the neuroscience of consciousness and mystical experience, including a study investigating the brain activity of Carmelite nuns. He is co-author of the book 'The Spiritual Brain: A Neuroscientist's Case for the Existence of the Soul'. SPONSORS http://amentara.com/go/dj - Use code DJ22 for 22% off. https://rag-bone.com - Use code DANNY & get 20% off sitewide. https://capl.onelink.me/vFut/zralgyl0 - Download CashApp today! https://chubbiesshorts.com/danny - Use code DANNY for 20% off. https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off EPISODE LINKS The Spiritual Brain - https://a.co/d/0cZDv6gn https://www.drmariobeauregard.com FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Dr. Beureguard's childhood mystical experience 03:52 - Discovering everything is connected as one 07:08 - Mario "downloaded" his life's mission 09:54 - Mario's failed journey to become a priest 15:44 - Mario's second mystical experience 21:08 - What Mario saw in Heaven 23:30 - Mario's biological markers say he's 20 years younger 29:19 - How Mario became a neuroscientist 30:07 - The roots of modern science 31:02 - When science lost its spiritual connection 34:27 - Testing memory molecules for Pfizer 36:00 - Pfizer pushed ineffective Alzheimer's drug in 1994 41:12 - Why Mario fled Canada during the pandemic 43:00 - Justin Trudeau paid off court judges during the pandemic 46:31 - The Catholic Church tried to bribe Mario 53:38 - Why the church is pushing new science 01:01:10 - Carmelite nuns study 01:07:00 - 1% of seizures trigger mystical experiences 01:09:57 - Johns Hopkins psychedelics + religion study 01:13:07 - Mario tested all drugs before experimenting 01:14:44 - Human psyche vs. consciousness 01:16:55 - "Consciousness" is the scientific God 01:21:56 - Non-physical information 01:25:17 - Where thoughts come from 01:30:14 - Holotropic breathwork to expand consciousness 01:34:58 - New consciousness research 01:38:02 - Who's funding consciousness research 01:40:11 - Studies on people who survived death 01:44:58 - Holosynthesis 01:49:33 - What happens when you "overdose" psychedelics 01:52:20 - Church-sanctioned psychedelic use 01:55:57 - Humans are behaving like robots 02:02:54 - Joan Jett's spiritual transformation 02:05:37 - NDEs vs. life reviews 02:07:21 - Memories of past lives 02:15:35 - How to expand consciousness using sound 02:21:30 - Bufo: DMT times 1,000 02:24:39 - Mapping neurological effects across religions 02:26:25 - The Dalai Lama's lesson on attention 02:32:04 - What the brains of uncontacted tribes might look like 02:37:55 - Explanation of the universe Learn more about your ad choices. Visit podcastchoices.com/adchoices

"The disease is increasingly managed as a chronic condition rather than a diagnosis with an immediate terminal outcome. Particularly, with earlier and more effective and sustained treatment options, we can make this disease a very chronic, long-term, livable condition. I want to make sure that patients are aware that this is not a death sentence. This is something that patients can live with for the long term," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term multiple myeloma considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 6, 2027. Ann McNeill is on the speakers' bureau for Pfizer. This financial relationship has been mitigated. All other planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to multiple myeloma and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 201: Which Survivorship Care Model Is Right for Your Patient? ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments Infection Prevention for Oncology Nurses Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Survivorship Programs Sexual Considerations for Patients With Cancer Oncology Nursing Forum articles:  A Qualitative Study of the Experiences of Living With Multiple Myeloma Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Huddle Cards: Pain Management Sexuality Survivorship Care Plan ONS Learning Libraries: Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship ONS Symptom Intervention resources: Chronic Pain Fatigue Peripheral Neuropathy American Cancer Society: Living as a Multiple Myeloma Survivor Blood Cancer United: Resources for Healthcare Professionals International Myeloma Foundation: Resources and Support for the Myeloma Community Multiple Myeloma Research Foundation: Empower Patients and the Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We do consider myeloma an incurable hematologic malignancy, even though we have had improvements in survival. But just like for any malignancy, our goal is to maximize survival. We want to eliminate as many myeloma cells as we possibly can. And subsequently, we want to improve the quality of life for these patients in the long term. So those are basically our treatment goals. That's what we think of when we're treating patients all throughout their treatment journey." TS 1:39 "It is very typical for patients along their journey to have received several lines of therapy. I think it's important to realize that the cells acquire new mutations, making them more resistant to these further subsequent lines of therapy. We see quicker, more aggressive relapses in those patients with multiple prior lines of therapy. We can see an increase in the CRAB symptoms, which are the calcium elevations, the renal dysfunction, profound anemia, and even bone disease. We can see a rapid rise in the monoclonal protein in the labs or even a very rapid rise in the involved light chain in that serum free light chain assay, so it's important to monitor these labs." TS 9:14 "All oncology nurses are focusing on these survivorship plans now. And I think that's a great thing when you think about a diagnosis of cancer and a survivorship plan, because it means these patients are living a longer time. We still look at long-term health maintenance guidelines depending on the patient's sex and their age. ... I think preventing infection is always going to be something absolutely on the forefront in our survivorship plan with myeloma. I mean, myeloma is an immune system malignancy. The treatments that we have given patients can sometimes, especially in later life therapies, further compromise the immune system. So, we're always looking to prevent serious infection." TS 12:46 "Patients get treatment, especially induction therapy. They may or may not get transplant. They may have been on a very minor maintenance schedule, depending on their age. And they feel really well. And then they decide not to return for their follow-up because they feel so good. I think nurses are critical in the communication aspect of the patient-provider aspect. So, nurses are really the key means of communication. The providers are absolutely important—the physicians, the nurse practitioners and every other member of the team—but I think the nurses have a really special rapport with patients. They're usually the ones providing the education on the treatment regimens. They're managing the toxicity profiles. They're doing all the coordination of care between visits. They are really going to be the ones telling the patient, 'Hey, you're going to feel good and that's a wonderful thing, but you still need to come once a month or once every six weeks or once every two months for your labs.'" TS 15:17  "It has been amazing. The science, the research, the treatments, the approvals from the U.S. Food and Drug Administration. Survivorship has improved dramatically. Let's take the first few years of the new century, right? The five-year survival rate was about 38%. If you then jump to 2015–2019, which is still seven plus years ago, it has doubled. So, we're talking about anywhere from 60%–80% over a five-year survival. So that's an amazing improvement in their five-year survival rate for myeloma." TS 23:28 "Survivorship in myeloma begins at diagnosis, not just after treatment. And I think that because it is managed as a chronic, often relapsing disease, it does require lifelong evolving care. Patients should realize that they will know us for the rest of their lives. We will know everything about you. I always tell them, 'I will know everything about your hobbies, your children, your grandchildren, what you love to do on the weekends.' It's very important that that point is made right at diagnosis, not just after so many lines of treatment. It's very important that we are going to follow these patients throughout their journey." TS 28:18

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

Nach Corona ist vor Corona. Jetzt sollen so gut wie alle herkömmlichen Impfungen ebenfalls auf mRNA umgestellt werden, auch für Kinder. Der Facharzt für Mikrobiologie und Infektionsepidemiologie, Prof. Sucharit Bhakdi und der ehemalige Chef-Toxikologe von Pfizer, Dr. Helmut Sterz befürchten dann eine geringere Lebenserwartung und den Ausbruch von Krankheiten wie Krebs und Alzheimer selbst bei Jüngeren. Ein Gespräch auch über brandneue Erkenntnisse zur C-Spritze, die Veränderung des menschlichen Genoms und über die Frage: Kann mRNA dumm machen? Ich würde mich freuen, wenn ihr meine unabhängige journalistische Arbeit unterstützt, damit ich auch in Zukunft weitermachen kann. Vielen Dank! Ich möchte mich auch ganz herzlich bei allen bedanken, die mich bereits unterstützen. Milena Preradovic Name: Milena Preradovic IBAN: AT40 2070 2000 2509 6694 BIC: SPFNAT21XXX oder https://paypal.me/punktpreradovic oder Cryptos Unterstützung in SOL und NAKMAK: 2CaVpf3NJEFdoUZeMAWvTK8aQzxQsMrgTBz5kWiH3Qvy Buchbestellung: „mRNA-Impfungen“: https://www.amazon.de/mRNA-Impfungen-gr%C3%B6%C3%9Fte-organisierte-Verbrechen-Menschheit/dp/3989921622  Und „mRNA-Impfungen“ beim Kopp-Verlag: https://www.kopp-verlag.de/a/mrna-impfungen-3?&6=77926540&otpcytokenid=77926540&CS=LB&ref=ppa Buchbestellung „Infektionen verstehen – statt fürchten“: https://www.kopp-verlag.at/a/infektionen-verstehennbsp%3B-statt-fuerchten?srsltid=AfmBOoqJ9JyWGWLZH2G1qeWk2TrAgOuEeqj0OiT8RRD3CATvZcYu4uzo Buchbestellung „Die Impfmafia“: https://www.buchkomplizen.de/unsere-komplizen/rubikon/die-impf-mafia.html Dr. Helmut Sterz bei Punkt.Preradovic: https://www.youtube.com/watch?v=Kmz6lBl6UeM Prof. Bhakdis Video „Aufruf an Impfgeschädigte der Chargen EX 8679, FD 7958, FE 6975“: https://www.youtube.com/watch?v=zSFaCUkWPow&t=7s  ........................................... Website: https://punkt-preradovic.com Odysee: https://odysee.com/@Punkt.PRERADOVIC:f Telegram: https://t.me/punktpreradovic Linkedin: https://www.linkedin.com/in/milena-preradovic-4a2836147/?originalSubdomain=at Twitter: https://twitter.com/punktpreradovic Facebook: https://www.facebook.com/punktpreradovic/ Instagram: https://www.instagram.com/punktpreradovic/ theplattform: https://theplattform.net #corona #mrna #pandemie #politik #wissenschaft

We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers;  The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Host: Sabiha Gati Guest: Thomas F. Luescher Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Send a textDr. Sharron Gargosky, Ph.D. is Chief Clinical Officer of Spinogenix, Inc. ( https://spinogenix.com/ ), a clinical-stage company pioneering a new class of therapeutics designed to reverse synaptic loss and dysfunction in the brain.Spinogenix is advancing two first-in-class oral small molecules. Tazbentetol is a synaptic regenerative therapy shown to regrow brain synapses — the vital connections between neurons. Clinical data have demonstrated rapid and significant improvements in memory and thinking in Alzheimer's disease, as well as clinically meaningful slowing of disease progression in ALS. The therapy is also being evaluated in schizophrenia, with a Phase 2 trial underway. Tazbentetol has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for ALS, and the company has established an Expanded Access Program to provide investigational treatment options to eligible ALS patients.Spinogenix's second program, SPG601, is a synaptic corrective therapy for Fragile X Syndrome — the leading inherited cause of intellectual disability and a known genetic driver of autism. Clinical data have shown normalization of abnormal brain activity patterns and improvements in attention and focus. SPG601 has received Orphan Drug and Fast Track Designations and is advancing toward late-stage development.Dr. Gargosky brings more than 25 years of global development leadership experience across small molecules, biologics, cell therapies, and diagnostics. She has overseen regulatory, CMC, non-clinical, clinical, and medical affairs programs across more than 15 countries, and has led multiple orphan and accelerated approval pathways.Previously, Dr. Gargosky held senior leadership roles at OncoSec Medical, Prima Biomed, Hyperion Therapeutics, Pfizer, and served in academia at Stanford University and Oregon Health & Science University.#Spinogenix #SynapticRegeneration #FragileX #AlzheimersResearch #ALSResearch #Neuroscience #BrainHealth #BiotechInnovation #Synaptopathy #ClinicalTrials #RegenerativeMedicine #Neurodevelopment #SharronGargoskySupport the show

Quels sont les médicaments réellement concernés par le risque d'ostéonécrose des mâchoires ? Quelle est la fréquence réelle de cette complication dans le cadre de l'ostéoporose par rapport aux pathologies malignes ? Comment mener un bilan dentaire pré-thérapeutique efficace et quelles sont les recommandations actuelles concernant la pose d'implants ou l'interruption des traitements ?Le Pr Vianney Descroix, chirurgien-dentiste (Université de Paris), et le Dr Catherine Beauvais, rhumatologue (Hôpital Saint-Antoine, Paris) nous éclairent à ce sujet.Nos invités déclarent ne pas avoir de lien d'intérêt en rapport avec le sujet traité.L'équipe :Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret, Dr Roba Ghossan.Animation : Marguerite de RodellecProduction : MedShake StudioSoutien institutionnel : Pfizer

Shawn Lipe is an art gallery and action house owner.  In this episode, he talks about how his collegiate exposure with Japanese culture changed his life, recognizing the moments to show up, knowing the kind of business you are in, the value in stories about your stuff, and the obligation of pivots.About the GuestOwner and gallery director at Woodard Lipe Fine Art and Auction, Shawn Lipe provides advisory strategies for private St. Louis art collections, gallery support, and facilitate institutional sales. Woodard Lipe auctions and Gallery provide a unique sales platform for art and fine collections, providing the highest level of representation. He appraises artwork for collection divestment or acquisition and work closely with a multidisciplinary staff to research and provide valuations of fine art, special collections, estate jewelry, vintage couture, classic automobiles, historic weaponry, fine Judaica, American folk, and American and European contemporary art, and sports memorabilia.In support of this mission, Woodard Lipe Fine Art and Auction provides CAGA certified appraisals for insurance loss recovery, fiduciary and trust equitable assets distribution, or probate and estate tax documentation. As a practicing artist and glass artist for the past 38 years, Shawn taught glassblowing as an adjunct professor in the Department of Art and Art History at the University of Miami, Coral Gables campus and maintained a private studio in Fort Lauderdale participating in both group and solo exhibitions. Additionally, he has conducted art research and curation at Wolfsonian Museum, Florida International University, and Krannert Art Museum at University of Illinois, Champaign-Urbana. Shawn received his Masters in Environmental Chemistry from SIU Edwardsville.. Professionally, he conducted research, chemical analysis, and drafted international regulatory documentation for Mallinckrodt Pharmaceuticals and was a past contributing senior regulatory affairs consultant for Cardinal Healthcare and Pfizer.To learn more, visit:linkedin.com/in/jason-Shupp-18b4619bListen to more episodes on Mission Matters:https://missionmatters.com/author/Jason-Shupp/

What if the greatest turnaround in modern corporate history wasn't driven by financial engineering or restructuring, but by an unshakeable belief in science and human talent? In this powerful episode of the Positive Leadership Podcast, I welcome Pascal Soriot, CEO of AstraZeneca—a visionary leader who transformed a struggling pharmaceutical company into a defining global force in oncology, cardiovascular disease, and respiratory care. He is also someone I know personally: I had the privilege of serving on the AstraZeneca board between 2008 and 2016, and I was in the boardroom when we appointed him as CEO. What makes Pascal's leadership so rare is his non-traditional ascent. He didn't start with an elite corporate playbook; his foundational lessons were grounded in learning the value of loyalty and protecting his people. By beginning his professional life as a practicing veterinarian, he developed a profound sense of empathy—traits that continue to drive his unwavering commitment to putting patients first today. But Pascal's story isn't your typical corporate trajectory. Raised in a humble background where he learned early lessons about loyalty, standing up for his team, and defending his territory, he began his professional life not in business, but as a veterinarian. It was this experience that profoundly shaped his empathy and his "patient-first" approach to leadership. In our conversation, we explore: 

It's been over two decades now since viagra was first approved for use in 1998, the little blue pill from Pfizer becoming the first oral treatment for erectile dysfunction. Its use has steadily increased over the years, with the NHS reporting just under 3 million prescriptions in 2016, compared to 1 million in 2006. Its success has led pharmaceutical companies to look for a female equivalent. In 2015, the American Food & Drug Authority approved a pink pill called Flibanserin, marketed as Addyi, which became known as female viagra. How does it work? Let's cut to the chase then; does female viagra really work? What can be done to help women who want to boost their libido? ⁠In under 3 minutes, we answer your questions!⁠ To listen to the last episodes, you can click here: ⁠⁠What is demisexuality?⁠⁠ ⁠⁠What is sologamy?⁠⁠ ⁠⁠What is intersectionality?⁠⁠ A podcast written and realised by Joseph Chance. First broadcast : 18/02/2022 Learn more about your ad choices. Visit megaphone.fm/adchoices

Brought to you by the Founders Unfiltered podcast by A Junior VC - Unscripted conversations with Indian founders about their story and the process of building a company. Hosted by Aviral and Mazin.Join us as we talk to Mazin about his journey and the experiences that shaped his path.He shared how A Junior VC evolved from a simple newsletter into a thriving community and eventually a fund, along with the lessons he learned along the way.We also dived into his journey of hosting the AJVC Unfiltered podcast alongside Aviral, and the conversations and insights that came from it.Mazin completed his BSE and MSE from University of Michigan and later pursued his MBA from INSEAD.Over the years, he worked across global organizations including Deloitte, Emirates NBD, and Pfizer.He is currently a Senior Product Manager at Agoda.

Dr. Peter McCullough — himself once vaccinated 69 times — explains in this in-depth conversation with Dr. Maria Hubmer-Mogg why he would no longer take a vaccine today, how the US CDC revised its position on vaccinations and autism after his report, and why three and a half years after the last Pfizer dose, mRNA is still detectable in the blood.

This week, we explore early colorectal cancer. Maybe it's just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or CAPOX. Josh digs a bit deeper and, as the name suggests, looks at whether patients with liver metastases can be cured with chemotherapy and a liver transplant.Studies discussed in this episode:IDEASTransMETEORTCFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we review advancements in migraine care and the standardization that can help physicians and other practitioners take the pain out of managing this condition, treating and preventing symptoms. https://drive.google.com/file/d/1YqEz5Ih_lmOnAk7nJsddfu8uXb3dYVjr/view?usp=sharing Supported by Pfizer

Support your health journey with our private practice! Explore comprehensive lab testing, functional assessments, and expert guidance for your wellness journey. Find exclusive offers for podcast listeners at nutritionwithjudy.com/podcast. _____Michael and I dive into how childhood trauma reshapes the nervous system, drives addiction, and contributes to chronic illness, mental health struggles, and even premature death. We break down the CDC's ACE (Adverse Childhood Experiences) score, including the powerful data showing that an ACE score is associated with losing years of life, and discuss why trauma may be the hidden driver behind inflammation, immune dysfunction, and chronic disease. Make sure to listen to the full interview to learn more.Michael Menard is an inventor, entrepreneur, and author who grew up as the second oldest of 14 children in Kankakee, Illinois, later discovering that he and his siblings experienced complex childhood trauma. As Vice President of Engineering at Johnson & Johnson, his 14 patents transformed global manufacturing, and his expertise has been sought by the United Nations, NASA, Coca-Cola, and Pfizer. He is the founder of United Against Childhood Trauma (UACT) and the bestselling author of multiple books, including The Kite That Couldn't Fly and Greater Than Gravity.We discuss the following: Who is Michael MenardTrauma's hidden death tollACEs defined by the CDCACE score shortens lifespanCortisol damages brain and bodyShame prevents trauma healingBuilding ACE 2.0 intensityWholeness and EMDR healingThe sacred first 60 daysThe Paradox of Childhood Trauma_____EPISODE RESOURCESUnited Against Childhood Trauma (UACT)WebsiteInstagramThe Kite That Couldn't Fly (Memoir)_____WEEKLY NEWSLETTER 

Why you should listenDoug Pelletier has spent 35 years winning enterprise accounts (Disney, Pfizer, Xerox) as a small Salesforce partner, proving that company size is irrelevant when your positioning and sales approach are right.Learn why Doug hired a General Manager at just six employees, and how that single WHO decision helped him scale to 130 people without burning out on tasks outside his strengths.Get Doug's approach to managing cash flow daily (a discipline he's maintained for 17 years) and why he says cash flow matters more than profitability for consulting firm owners.About Doug PelletierDoug Pelletier is the Founder and CEO of Trifecta Technologies, a technology consulting firm he launched in 1991 that has grown into a trusted Salesforce and enterprise solutions partner for leading organizations. A sales- and strategy-led founder, Doug focuses on identifying real business problems, building executive relationships, and hiring strong operational leadership early – allowing him to concentrate on growth, client strategy, and selling. His leadership is shaped by decades of experience and a strong emphasis on financial discipline and long-term stability. Having gone through multiple industry shifts, Doug views AI as a major inflection point and leads Trifecta in helping organizations move beyond the hype to apply data, architecture and AI in practical ways that drive meaningful business outcomes. Resources and LinksTrifecta.comDoug's LinkedIn profileSnowflakeDatabricksApolloZoominfoPrevious episode: 667 - The Land-and-Expand PlayCheck out more episodes of the Paul Higgins PodcastSubscribe to our YouTube channel: @PaulHigginsMentoringJoin our newsletterSuggested resources

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Measuring AI marketing ROI has become one of the most uncomfortable conversations in tech and marketing teams. Everyone knows AI is "important." Fewer teams can explain what success actually looks like. Even fewer can tie adoption to real outcomes rather than experimentation for its own sake. For developers and technical leaders, this isn't a tooling problem — it's a decision-making problem. The teams that win are the ones that slow down just enough to define value before they ship. About Meeky Hwang Meeky Hwang's journey resonates with entrepreneurs, technical leaders, and anyone navigating the intersection of technology and business. As CEO and Co-Founder of Ndevr, a digital solutions development agency, Meeky brings over 20 years of experience building resilient, scalable platforms for organizations including Johnson & Johnson, Pfizer, Forbes, PMC, and Bloomberg. Her work goes beyond website development—she focuses on long-term digital solutions that improve performance, streamline workflows, and align technology with business strategy. Equally important is Meeky's perspective as a woman leading in a male-dominated industry. She has navigated the challenges of technical leadership, entrepreneurship, and scaling a services business while building credibility and strong teams along the way. Her experience offers an honest look at what it takes to grow as a leader without losing sight of innovation, people, or purpose. Follow on LinkedIn and her Website. Measuring AI marketing ROI when the hype is louder than the data AI adoption today often starts with pressure instead of purpose. Tools arrive before goals. Budgets get approved before success criteria exist. That's the first red flag. If you can't articulate what improvement AI is supposed to create — conversion lift, content velocity, operational savings, personalization accuracy — you're not measuring ROI. You're chasing momentum. Measuring AI marketing ROI by defining outcomes before tools The most effective teams reverse the typical process. They define outcomes first, then ask which capabilities might support those outcomes. That discipline alone filters out most bad investments. Before selecting tools, answer three questions: What problem are we solving? How will we measure improvement? What happens if this fails? If those answers feel vague, that's your signal to pause. Measuring AI marketing ROI with clear baselines and success metrics ROI requires comparison. Without a baseline, every result looks impressive — or disappointing — depending on expectations. Establish: A pre-AI performance baseline A specific success threshold A review window short enough to stop bad bets early This turns AI from a belief system into an experiment with guardrails. Measuring AI marketing ROI without wasting budget on "maybe" features Not every feature deserves implementation just because it exists. Time and money are always the real constraints. Teams that succeed evaluate AI features the same way they evaluate architecture decisions: cost, risk, effort, and impact. When those tradeoffs are visible, priorities clarify quickly. Measuring AI marketing ROI while Google, SEO, and platforms keep shifting AI doesn't exist in isolation. SEO changes, platform updates, and algorithm shifts constantly reshape the playing field. That makes flexibility more valuable than novelty. Incremental improvements that survive change often outperform bold implementations that lock teams into fragile solutions. Measuring AI marketing ROI alongside compliance requirements and regional rules Global websites introduce real constraints — privacy, consent, accessibility, and regulatory differences. AI features that ignore compliance increase risk faster than they increase value. Measuring AI marketing ROI with a repeatable compliance checklist A checklist-driven approach ensures new features don't break trust or regulation: Regional consent and privacy rules Accessibility requirements Data handling expectations This protects ROI by preventing costly rework. Measuring AI marketing ROI through discovery, QA, UAT, and launch checklists Strong discovery reduces downstream chaos. Structured QA and UAT validate assumptions. Launch checklists prevent avoidable mistakes. AI doesn't replace these fundamentals — it amplifies their importance. Measuring AI marketing ROI as a founder: delegate, stay lean, and still scale Technical founders often delay hiring because they can do the work themselves. That works — until it doesn't. Sustainable ROI requires delegation. Growth depends on trusting others to execute while leaders focus on direction, not tickets. Callout: AI ROI Scorecard Define outcomes, baselines, and review windows before implementation Decide early whether to pilot, pause, or proceed Callout: Website Launch Checklist (Minimum Viable) QA, UAT, accessibility, and responsiveness checks Hosting, CDN, and integration validation Callout: Delegation Rules for Technical Founders Decide what you keep vs. hand off Train once, so execution scales later Conclusion Measuring AI marketing ROI isn't about skepticism — it's about clarity. When teams define value first, use disciplined checklists, and resist hype-driven decisions, AI becomes a multiplier instead of a distraction. If you want better outcomes, start with better questions — and build from there. Stay Connected: Join the Developreneur Community We invite you to join our community and share your coding journey with us. Whether you're a seasoned developer or just starting, there's always room to learn and grow together. Contact us at info@develpreneur.com with your questions, feedback, or suggestions for future episodes. Together, let's continue exploring the exciting world of software development. Additional Resources Online Communities and Marketing Creating your Marketing Site Branding and Marketing Fundamentals with Kevin Adelsberger Develpreneur - Forward Momentum Podcast Videos – With Bonus Content

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Guest: Martin Brenner, Ph.D., Chief Executive Officer and Chief Scientific Officer at iBioCompany: iBio, Inc. (NASDAQ:IBIO)Website: https://ibioinc.com/Martin's Bio:Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, he was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, he was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Company Description: iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. iBio's mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

At Pfizer, the employer brand is an experiment in progress where hypotheses are constantly tested to improve activation. We learn how they measure their progress as they go and weave employer brand concepts into the recruitment process. Anne Kennedy Dotson is the Global Head of Employer Brand, Recruitment Marketing & University Relations at Pfizer. Anne Kennedy Dotson on LinkedIn: https://www.linkedin.com/in/anne-kennedy-dotson-8362128/ Careers at Pfizer: https://www.pfizer.com/about/careers Subscribe to this podcast: https://employerbrandingpodcast.com Measure your employer brand: https://employerbrandindex.co Thanks for tuning in!

The Developer to CEO transition rarely starts with a bold declaration like, "I'm going to run a company." More often, it begins quietly—by taking on one more responsibility, saying yes to a new opportunity, or stepping into a role that stretches just a little beyond your comfort zone. In this episode of the Building Better Developers podcast, part of our Forward Momentum season, we talk with Meeky Hwang about how that transition unfolds in real life. Her path—from developer to agency founder and CEO—reflects a pattern many experienced engineers recognize only in hindsight. Over time, those small decisions add up. You stop thinking only about code and start thinking about people, clients, sustainability, and direction. At some point, you realize you're no longer just building software—you're building a business. About Meeky Hwang Meeky Hwang's journey resonates with entrepreneurs, technical leaders, and anyone navigating the intersection of technology and business. As CEO and Co-Founder of Ndevr, a digital solutions development agency, Meeky brings over 20 years of experience building resilient, scalable platforms for organizations including Johnson & Johnson, Pfizer, Forbes, PMC, and Bloomberg. Her work goes beyond website development—she focuses on long-term digital solutions that improve performance, streamline workflows, and align technology with business strategy. Equally important is Meeky's perspective as a woman leading in a male-dominated industry. She has navigated the challenges of technical leadership, entrepreneurship, and scaling a services business while building credibility and strong teams along the way. Her experience offers an honest look at what it takes to grow as a leader without losing sight of innovation, people, or purpose. Follow on LinkedIn and her Website. Developer to CEO transition starts with "accidental" opportunities For many engineers, this transition begins almost by accident. A consulting role exposes you to different industries. A startup forces you to wear multiple hats. An agency environment teaches you how delivery, relationships, and trust intersect. None of these roles comes with a "future CEO" label. But they do build instincts—how to prioritize, how to adapt, and how to make tradeoffs when perfect solutions aren't possible. Those instincts matter far more than a perfectly mapped career plan. Developer to CEO transition lessons from consulting, startups, and agencies Each environment contributes something different to the Developer to CEO transition. Consulting sharpens communication and expectation-setting. Startups teach ownership and resilience. Agencies reveal what it takes to scale work without burning people out. Individually, these roles can feel chaotic. Together, they form a foundation that prepares developers for leadership long before they realize that's where they're headed. Developer to CEO transition and the mindset shift to full responsibility There's a moment in the transition when responsibility feels heavier. Decisions don't stop at your team or your sprint—they ripple outward. Hiring, pricing, client relationships, and long-term viability all land on your plate. Problems are no longer theoretical. They're personal. This shift changes how leaders think. It forces clarity, prioritization, and the ability to move forward without perfect information. Developer to CEO transition accelerators: mastermind and founder groups One of the most impactful accelerators in the Developer to CEO transition is joining founder communities earlier than you think you need them. Mastermind ROI for New Owners Real conversations about hiring, benefits, pricing, and mistakes Exposure to how other founders actually run their businesses Founder groups shorten the learning curve by replacing isolation with shared experience. Instead of guessing, you learn from people who've already been there. Developer to CEO transition accountability: learning faster through peers Accountability is often underestimated in the Developer to CEO transition. Founder groups create a rhythm of progress—not through pressure, but through shared momentum. The "Accidental" Path That Works Follow opportunities that increase learning, not just status Optimize early for exposure and experience, not polish When you know you'll report back to peers who care, progress stops being optional. Developer to CEO transition when your role forces personal growth The Developer to CEO transition also reshapes how leaders show up. Many founders start as quiet contributors, comfortable behind the scenes. Leadership changes that. Mindset Shifts in the Developer to CEO transition Responsibility changes how decisions feel—and how quickly they must be made Visibility and communication become part of the job Growth here isn't about changing who you are. It's about growing into what the role requires. Developer to CEO transition and evolving the agency niche over time As companies mature, the Developer to CEO transition continues through strategic evolution. Niches tighten, then expand. Focus shifts based on market feedback, strengths, and timing. The most successful agencies don't chase trends. They adjust deliberately, guided by experience rather than impulse. Developer to CEO transition: what to do earlier if you could restart Ask founders what they'd change, and many give the same answer: find peer support sooner. The Developer to CEO transition becomes clearer—and far less lonely—when you're not navigating it in isolation. This episode of the Building Better Developers podcast is a reminder that growth doesn't come from having all the answers. It comes from asking better questions, learning from others, and building momentum—one decision at a time. Stay Connected: Join the Developreneur Community We invite you to join our community and share your coding journey with us. Whether you're a seasoned developer or just starting, there's always room to learn and grow together. Contact us at info@develpreneur.com with your questions, feedback, or suggestions for future episodes. Together, let's continue exploring the exciting world of software development. Additional Resources Maintaining Momentum And Steady Progress Consistency And Momentum: Keys To Success New Year, New Momentum: What Developers Can Look Forward to in 2026 Habits, Roadmaps, and the Value of Career Momentum Building Better Foundations Podcast Videos – With Bonus Content

Over 1.5million adults in the UK tried weight loss drugs in 2024-25. Many swear by them, but they have been associated with side effects including nausea and, in some cases, extremely painful gallstones. But what does the evidence actually tell us, and what is the wider impact on the way we view our bodies in society?James Gallagher is joined by Professor of Cardiometabolic Medicine at the University of Glasgow Naveed Sattar, Dr Beverley O'Hara, Lecturer in Public Health Nutrition at Leeds Beckett University, and Dr Margaret McCartney, resident Inside Health GP. They discuss what the evidence tells us about the potential known side effects of these weight loss drugs, and the potential impact their use has on our view of obesity as a society. We also hear from Sarah Le Brocq, who has struggled with obesity all her adult life and has been on these drugs for the past 2-3 years about her experiences. Margaret McCartney has no conflicts of interest to declare.Beverley O'Hara has no conflicts of interest to declare. She has 2 roles with the Association for the Study of Obesity (voluntary academic positions).Naveed Sattar has consulted for and/or received speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Verdiva Bio; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche.Presenter: James Gallagher Producer: Hannah Fisher Researcher: Tom Hunt Production coordinator: Stuart Laws Content Editor: Ilan Goodman

Max Martina on Mastering Adaptive Leadership for Complex Challenges in Modern Business Cambridge-leadership.com About the Guest(s): Max Martina is an accomplished leader in the field of change leadership, currently serving as the President of Cambridge Leadership Associates, a prominent consultancy founded at Harvard’s Kennedy School of Government. With a robust background spanning over two decades in corporate management and startups, Max is also a partner at the executive advisory firm Nofsinger Group. His extensive consultancy expertise encompasses working with C-suite and board-level executives across both public and private sectors, with clients including major companies such as PepsiCo, IHG, Microsoft, Pfizer, Amgen, and Intel, along with organizations like the United Nations. Max has been featured in media outlets including CNN, NPR, and MSNBC and brings a wealth of knowledge to the realm of leadership consulting. Episode Summary: In this engaging episode of the Chris Voss Show, host Chris Voss welcomes Max Martina, a distinguished leader in change leadership, to explore the current dynamics and the pressing need for adaptive leadership in today’s fast-evolving world. The conversation delves into the intricacies of adaptive leadership, contrasting traditional models and emphasizing the necessity for a flexible, behavior-focused approach to tackle complex issues within organizations. Listeners get an in-depth look at how leadership is evolving with the rapid rise of AI, economical upheavals, and global challenges. Throughout the discussion, Voss and Martina highlight the notion that leadership is not synonymous with authority and that true leaders are those who practice and exhibit flexible behaviors suited to ever-changing environments. They explore the limitations of traditional leadership dogmas, such as trait theory, and the advantages of adaptive leadership, grounded in behavior and self-awareness. Martina shares insights into how executives can foster an environment that thrives amidst uncertainty, focusing on critical areas such as diagnostics, experimentation, and the shift from individual contributors to team-based leadership. This episode is a valuable resource for anyone interested in understanding modern leadership dynamics and how to apply these principles effectively. Key Takeaways: Adaptive leadership diverges from traditional theories, focusing on flexibility and behaviors over positions of authority. The need for self-awareness and behavior change is critical for effective leadership, particularly amid today’s rapid technological advancements. Adaptive leadership emphasizes diagnostics and experimentation in solving complex, adaptive problems that cannot be addressed by technical solutions alone. Building organizational capacity involves shifting from a focus on individual execution to fostering a conducive environment that supports collective learning and problem-solving. With AI driving unprecedented changes, the necessity for adaptive leadership has become more pronounced to keep up with the escalating rate of transformation. Notable Quotes: “Leadership isn’t about having authority; it’s about practicing certain behaviors regardless of your role or title.” “We’re outpacing humanity’s ability to respond systemically to the complexity that exists, and the antidote is leadership.” “Change isn’t hard, but adapting to the losses that change brings is what challenges us the most.” “Successful leadership requires diagnostics – understanding the source of the problem and the stakeholders involved.” “Organizations today need leaders who can not only solve problems but are curious enough to experiment and find new solutions.”

Gregory Zuckerman describes the climactic moment vaccine results arrived, with Pfizer and Moderna reporting high efficacy, while Novavax and AstraZeneca faced unique logistical and reputational challenges. 7

Send a textA newborn brain can feel the pulse before it knows the tune—and that single insight opens a door into how early our minds start to organize the world. We kick off the new season by exploring two studies that hit close to home: one revealing that infants build visual categories and detect musical rhythm far earlier than many assumed, and another mapping the real‑world challenges older adults face when caring for pets they deeply love. The data is surprising, the implications are practical, and the thread running through it all is how we turn evidence into everyday decisions.Our guest, Dr. Raven the Science Maven, brings sharp insight and contagious energy to the bigger question: how do we bridge science and public life? From molecular biology to a PhD focused on communication, from catchy vaccine tracks to hosting Pfizer's Science Will Win, Raven shows how storytelling, music, and personal narrative make complex ideas land. We talk institutional barriers, the pandemic's hard lessons, why every science degree should include communication training, and how her nonprofit, The Science Haven, sparks curiosity with projects like Stellar Dreams.If you enjoy smart, human stories that connect lab findings to daily choices, tap play, subscribe, and share with a friend who loves science and pets. And if you care about better SciComm in higher education, go to make science make sense.com and add your name. Your voice helps science reach the people it's meant to serve.Dr. Baxter's Website - you'll find her podcast link and social media links hereOur links - you'll find all of our social links and website links hereSupport the showFor Science, Empathy, and Cuteness!Being Kind is a Superpower. All our social links are here!

From Music to Medicine: Rethinking Clinical Trials, AI, and Real-World Evidence On this episode Gil and Gregg welcome Amir Lahav, MD, ScD, founder and CEO of SkyMedAI and curator of the Digital Health AI Innovation Summit in Boston. Dr. Lahav traces his unlikely path from working musician to Harvard Medical School faculty, Pfizer rare-disease innovator, and now advisor to digital health and life sciences companies. The conversation explores how music-driven neurorehabilitation helped stroke survivors regain motor function, why traditional snapshot-based clinical trials are “embarrassingly wrong” for real-world patients, and how AI and wearables can turn continuous data into earlier detection and more humane care. Lahav also warns about overconfident, under-validated AI and argues that the most successful health companies by 2030 will be those that know when not to use AI. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.Studies discussed in this episode:MAPSCheckmate 743For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Few issues have tested public trust in medicine as deeply as vaccines, and few individuals have influenced that dialogue more than Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a longtime member of the FDA's Vaccine Advisory Committee. In this timely and candid interview with Raise the Line host Lindsey Smith, Dr. Offit points to this year's severe flu season and a resurgence of measles as alarming proof points of how a changing federal perspective on vaccine policy is having a real impact on public health. “You'd like to think you can educate about the importance of vaccines, but I fear at this point the viruses themselves are doing the educating.” In this wide ranging discussion, Dr. Offit also addresses: The rigorous and painstaking process of developing vaccines, based on his experience co-inventing the rotavirus vaccine. Shifting levels of public trust in scientific organizations. Promising innovations in vaccine development. Don't miss this deeply-informed perspective on the interplay of science, policy, and public education, and his encouraging message to young clinicians about managing the current challenges in public health.  Mentioned in this episode: Vaccine Education Center at Children's Hospital of PhiladelphiaPerelman School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Dr. Monty Pal and Dr. Ari Rosenberg discuss the evolution of treatment strategies in head and neck cancers, including the challenges of treating both HPV-positive and HPV-negative disease and the emergence of blood-based biomarkers to advance personalized therapy across different subtypes. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, we're going to explore the evolving landscape of treatment strategies in head and neck cancer management, including locoregionally advanced head and neck squamous cell carcinoma, which happens to be on the rise in United States, in part due to spike in HPV-mediated oropharyngeal cancers. We're also going to discuss the emerging strategies of using blood-based biomarkers to really advance personalized therapy. Joining me for this discussion is Dr. Ari Rosenberg. He's a medical oncologist focused on head and neck cancer, and he's an associate professor – congratulations on the recent promotion – at the University of Chicago. The University of Chicago has really produced luminaries in this field, Dr. Rosenberg included. I've had the pleasure of getting to know Dr. Ezra Cohen over the years, who really had his grounding there, and of course Everett Vokes, former ASCO President. I'm really looking forward to this conversation, Ari. Thanks so much for joining us. Dr. Ari Rosenberg: Thanks, Monty. Thanks for the invitation. Dr. Monty Pal: You got it. And just a quick note for our listeners, our full disclosures are going to be in the transcript at the end of this episode. So let's start with the basics, if you don't mind. So, head and neck cancers are very diverse and they're challenging, right? In the sense that they're near vital organs, the treatments, you know, as we all saw during fellowship, if not now in clinical practice. They can really have such a major impact on vital organ function, speech, swallowing, et cetera. Can you just comment on head and neck cancers that are on the rise in the U.S.? I alluded to this briefly. Particularly, we've heard this in the context of colorectal cancer and so forth. Are you actually seeing younger adults being affected by this? Dr. Ari Rosenberg: Yeah, thanks for that. The vast majority of head and neck cancers are head and neck squamous cell carcinomas, as I'm sure many of the listeners recall as well from fellowship or their current training. And as you alluded to, the organ function, long-term and functional quality of life outcomes are quite important, particularly in the context that these develop in high value real estate, parts of our head and neck area that we use for speaking, swallowing, all sorts of other essential functions as well. As you also alluded to, we think of this in two different particular subtypes of head and neck cancer. The historical head and neck cancer from 50, 60 years ago was almost exclusively related to carcinogen exposure, tobacco, alcohol use, and that subtype of carcinogen-induced head and neck cancer has been slowly declining. However, over the last now several decades, we've been seeing an increase in primary oropharyngeal squamous cell carcinoma, mostly tonsil, base of tongue. These are attributable to HPV, human papillomavirus exposure. And that's now the majority of the head and neck cancers that we tend to see in our clinic. As you also alluded to, these have very different prognoses as well. HPV-related head and neck cancer has a much more favorable prognosis where much of the interest has been in can we de-intensify to optimize long-term function? But then the non-HPV-related head and neck cancer, or what we call HPV-negative head and neck cancer, continue to be very, very challenging. We only managed to cure about half of these folks, with many of these patients developing the current disease. These patients, in addition to being difficult to treat, also have major impacts both in terms of the treatments they undergo as well as their disease that can impact their function and quality of life. And you hinted at this a little bit, but we have been seeing an increase in younger patients with HPV-negative head and neck cancer as well, which is quite concerning. Younger patients, oftentimes never smokers, never drinkers, who are developing non-HPV-negative head and neck cancer. And that's been a little bit of a more recent trend that we've been seeing as well. So, definitely a lot of work to be done to optimize and improve outcomes across all of these different head and neck cancer subtypes. Dr. Monty Pal: I mean, I'm just curious, you know, in the context of colorectal cancer, one of the things that we talk about is the potential role of the microbiome driving some of these young-onset cancers with, you know, perhaps there being an impact on, for instance, inflammation and the gut and what have you. Tell me about head and neck cancer. Is this anything known as to why younger patients might be getting diagnosed with non-HPV type cancers? It's odd to me. Dr. Ari Rosenberg: Yeah, it's a great question. A lot of people are working on it. I think we folks have hypotheses, but it hasn't totally panned out exactly what's going on there. It does have a little bit more of a tendency towards women, whereas historically head and neck cancer is much more common in men than it is in women. But lots of people working on that, whether it's related to chronic inflammation, whether it's related to the microbiome. Whether it's related to dental exposure, dental work. So, a lot of folks trying to parse that out because I agree with you, it needs to be identified alongside improving treatment paradigms for these patients, the young ones and the older patients as well. Dr. Monty Pal: Interesting, interesting. You know, one of the phenomena that was sort of coming around when I was in training 25 years ago was this role of sort of induction therapy for head and neck cancers. And of course, it's really come full circle now to include checkpoint inhibitors and so forth. Tell me a little bit about this and how you apply it, maybe in an HPV-mediated context, maybe in a non-HPV context. Dr. Ari Rosenberg: Yeah, absolutely. Induction chemotherapy, as you alluded to, or neoadjuvant chemotherapy, depending on what the locoregional treatment approach is. Similar to other cancer types where systemic control early on has many potential advantages in this setting. Now, in head and neck cancer, even though induction chemotherapy is quite active in head and neck cancer, both HPV-positive and HPV-negative with pretty good response rates. A survival advantage for all comers with local regionally advanced disease remains unproven. There's been two randomized trials, both underpowered, but essentially did not show a survival advantage, showing that induction chemotherapy for all patients with locoregionally advanced and neck cancer can't be justified for a survival advantage. That being said though, there remains a number of potential advantages of giving induction or neoadjuvant chemotherapy, of course, improving systemic control and debulking the disease early on has potential advantages, and predicting the responsiveness to subsequent radiation treatment. We know for some time in head and neck cancer that the percentage of shrinkage or the response to induction chemotherapy actually predicts outcome related to radiation as a dynamic biomarker where response can be used to select patients, for example, for de-escalated radiation has been an area of active investigation, active research. And it also remains a key opportunity to evaluate predictive biomarkers and understanding pre and post treatment to better understand the biology. I'll just add to your question that recently over this past year, we also saw phase 3 data for neoadjuvant immunotherapy for a subset of head and neck cancer that is surgically resectable. And so that's reintroducing the potential benefit in the immunotherapy era of incorporating immunotherapy in the neoadjuvant or the induction setting as part of the evolving treatment paradigm for these diseases. Dr. Monty Pal: That's really interesting. And you kind of alluded to already several topics that I plan to hit on, you know, for instance, the role of immune checkpoint inhibitors, induction, chemotherapy, and so forth. And you started to touch on biomarkers. And of course, I think that's something near and dear to many of us in academic oncology. One thing that we've started talking a lot about in the context of colorectal cancer is circulating tumor DNA. How do you think this might fit in the context of head and neck cancer? Can you give us a flavor for that? Dr. Ari Rosenberg: Yeah, absolutely. In head and neck cancer, the current landscape is most developed for circulating tumor DNA for HPV-related head and neck cancer. The advantage of HPV-related head neck cancer is that you have a distinctive HPV DNA that does tend to spill out into the peripheral blood and can be detected using various different blood-based assays. And because of that advantage as a tissue agnostic approach, it turns out that a number of HPV DNA plasma assays are actually quite sensitive and quite specific. And a number of them have indeed been commercialized. Of course, not only for detecting a baseline, but also grading responsiveness during treatment and probably most importantly in the post-treatment surveillance setting, the detection of HPV DNA in the plasma remains a very important and substantial predictor of developing recurrent disease. There's been a number of trials that have been emerging looking at ctDNA and HPV-related head and neck cancer, using it, for example, as a strategy to deescalate patients. That was something we saw this past ASCO from the Dana-Farber group, and also using it to early detect recurrence and potentially intervene earlier for patients with minimal residual disease positivity. So, that remains evolving and as many folks are, I think, already using it in the clinic. But ctDNA also has a lot of potential for HPV-negative head and neck cancer. This is actually a bit more challenging to develop because you don't have that HPV DNA that you can track predictably because the tumor is an HPV- negative disease are much more heterogeneous, but there are a number of data that are coming out both for personalized assays such as Signatera or some of the other assays that require tumor. Unlike colon cancer, which you referenced, where most patients get surgery upfront, in head and neck cancer, many of the patients receive non-surgical pre-chemoradiation. So sometimes the amount of tumor available to generate a personalized assay is more limited and can be one of the challenges that we see in head neck cancer. But certainly that also seems to be emerging. And there's also further assays that are being developed for HPV-negative head neck cancers, such as methylomic signatures and others that may be tissue informed or tissue agnostic. And these are also emerging, particularly in the post-treatment surveillance setting as strong predictors of recurrent disease. So while we're certainly behind some of these other more common tumor types, colon cancer, lung cancer, we're right there with them and more and more trials are going report out, including a number of trials in our upcoming [University of Chicago] Head and Neck Cancer Symposium where I'll be presenting some data and others in the field will be presenting some data looking at ctDNA both for HPV-positive and for HPV- negative to try to improve outcomes for these patients. Dr. Monty Pal: That's so interesting. I've got to tell you that in kidney cancer, what I deal with day to day is a very low shedding disease, right? So techniques as opposed to ctDNA looking for tumor-informed information, that might be less preferred to something like methylomics where you might not necessarily be so contingent on what's happening in the primary tumor. I'm really interested in you mentioning that. Just a point of clarification, this is something I'm trying to wrap my head around. You'd mentioned circulating tumor HPV DNA, right? I assume this is markedly different from just looking for HPV titers in the patient, right? So is this actually incorporated elements of HPV within, you know, essentially host genome, if you will? Dr. Ari Rosenberg: Yeah, correct. This is circulating tumor HPV DNA. And we think of it biologically as a plasma-based tumor DNA biomarker that's specific for HPV-related head and neck cancers. Dr. Monty Pal: Got it, got it. It makes me wonder whether or not this might be applicable to diseases like cervical cancer and so forth where there's also extensively, you know, biology driven by HPV. Is that fair? Dr. Ari Rosenberg: Yes, definitely. And in the head and neck cancer field, much of this ctDNA actually was derived from a different viral mediated head neck cancer, is less common in the U.S., but nasopharyngeal cancer, which is oftentimes associated with EBV. That has been a biomarker for quite some time in nasopharyngeal cancer. Of course, in places where EBV-associated nasopharyngeal cancer, is endemic, such as East Asia, this has been around for quite some time, but we've been using that in the U.S., and there's been trials that have used EBV DNA plasma to predict recurrence and stratify for adjuvant treatment, for example. And so now with HPV, it's much more applicable to our US population because the vast majority of our head and neck cancer patients that we see in the US that are viral mediated in the US tend to be HPV-related. So having assays that we can use to improve outcomes for that biological subset remains of particular interest for us. Dr. Monty Pal: Yeah, that's fascinating. By the way, for the fellows listening, there's tons of boards pearls here that Dr. Rosenberg shared, EBV-associated cancers, the role of HPV and treatment association. So if you're recertifying anytime soon, I definitely think there's notes to take from this conversation indeed. I wanted to shift gears a little bit. And obviously, you're a prolific researcher. I don't think anyone goes through their fellowship in medical oncology without recounting these experiences of our head and neck patients really suffering from treatment-related toxicities. It's a real challenge. And I'm just wondering, I know a big body of work that you're focused on is really using multimodality treatment paradigms to perhaps reduce the cumulative treatment burden of patients with head and neck cancers. Can you talk about that a little bit? Dr. Ari Rosenberg: Yeah, definitely. Thanks for the question. And before I start going into some of the strategies, I'll just say that head and neck cancer, this is particularly for the fellows that are listening as well, just in reference to your prior comment, that this is really a multidisciplinary disease. At our center, all head and neck cancer patients are seen upfront at that first visit by all three specialties, med onc, rad onc, and surgery, because the choice and sequencing of modalities to optimize not only survival, but also functional quality of life outcome is so critical. And I think that's probably the biggest takeaway for anyone who treats a lot of head and neck cancer or will be treating a lot of head and neck cancer in the clinic. But in terms of more specific attempts at trying to optimize some of those parameters that you described, we really think about these separately in terms of HPV-positive and HPV-negative head and neck cancer. For HPV-positive head and neck cancer, the cure rates are quite high with chemo radiation, although not for everyone. There's still about 15, 10 to 15 % of folks that will develop a recurrence. But for the vast majority of patients, standard chemoradiation is quite a cure to therapy, but the toxicity associated with that can be quite substantial. And so there's been a number of attempts to try to deescalate treatment. It turns out that deescalating everyone with locoregionally advanced HPV-positive head and neck cancer is not a good strategy because it's not able to select out the patients that really do need full dose treatment. And we have seen some negative trials that show inferior outcomes when everyone is deescalated. But what does remain promising is again, trying to select out who the best candidates are for deescalated treatment. The folks at MSK have hypoxia imaging that they're using in trials that looks quite promising to select for the more favorable deescalatable biology. At our center, we've been interested in using induction chemotherapy to stratify response and select patients for deescalated treatment with excellent survival outcomes and reduce toxicity with deescalated treatment. And more recently, ctDNA that us and other groups, such as the Dana-Farber group, is using. And that also looks quite promising. Again, how do you select the patient who will do well with less radiation versus the ones that really need the full doses and volumes of radiation? And then for HPV-negative head and neck cancer, this is a much trickier disease because already the survival outcomes are not like we want it to be. Trying to figure out how to improve survival outcomes remains an important thing. Using immunotherapy seems to be one of the key cornerstones to that. But these are patients that also suffer from a lot of toxicity related to their treatment. We completed a trial not too long ago that we published this past year where we, in HPV-negative head and neck cancer patients, de-intensified the radiation for responders to neoadjuvant chemoimmunotherapy. And those patients did similar, if not even a little bit better, than the non-responders who got full dose treatment. So something that does warrant further investigation as well. How do we not only improve survival for those patients, but also reduce some of the long-term toxicities? Dr. Monty Pal: This is brilliant. I'm taking so many notes as you were mentioning these items. There are so many areas where I think the research crosses over. I already mentioned, know, ctDNA, for instance, and metabolomics and the places where that might apply to kidney cancer. The hypoxia imaging really caught my ear too. Obviously, kidney cancer is disease highly predicated on hypoxia. So thank you for all of this. We've got about a minute or so. So, I'm going to ask you for a really tall task here. Can you tell us what you foresee being some of the biggest challenges that sort of lie ahead and head and neck cancer. You've already kind of alluded to it with ongoing research, but if you had to pick maybe 2, 3 problems, the very most that we really need to get to and head and neck cancer, what would that be? Dr. Ari Rosenberg: Yeah, that's a great question. Obviously, lots of things to be done, but if I'm going to limit it to just a couple, I would say number one is really trying to improve the survival for HPV negative local regionally advanced head and neck cancer. We talked early on about how we are seeing, you know, of course we see many of these people that were smokers and drinkers, but also seeing these in younger patients, in patients without a history of tobacco use. Some of these are very biologically aggressive and we need better treatments beyond surgery, beyond chemo radiation, beyond immunotherapy to improve outcomes for these patients and cure more of them. So, I would say that's one big area. And the other is, which we didn't speak about so much in this talk, but remains one of the biggest challenges that we see in the clinic is the recurrent metastatic head and neck cancer patients. This is an incredibly challenging disease to treat, not only with poor survival, but also with substantial impacts on quality of life and function. mean, these are bad recurrences that cause a lot of pain, functional deficits, really impacts quality of life as well. So developing novel therapies, many of which are currently in clinical trials and many of which are currently continuing to be developed, remains so critical. How do we develop better systemic therapies, better targeted therapies, better biomarkers for recurrent metastatic head neck cancer to improve their survival and quality of life and functional outcomes. Those are the two big areas that require the most work at this time within the head and neck cancer field. Dr. Monty Pal: That's brilliant. I mean, I have to tell you I could probably talk to you all day about this, such a fascinating topic. It's a very exciting time in the field. Thank you, Dr. Rosenberg, for all your incredible contributions and thanks for sharing with us your insights on the ASCO Daily News Podcast. Dr. Ari Rosenberg: Yeah, and thanks for the introduction. Hope to do it again soon. Dr. Monty Pal: And many thanks to our listeners for your time today. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. More on today's speakers:      Dr. Monty Pal   @montypal  Dr. Ari Rosenberg @AriRosenbergMD Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:       Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical      Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Ari Rosenberg:     Stock and Other Ownership Interests: Privo Technologies Consulting or Advisory Role: Nanobiotix, EMD Serono, Vaccitech, Novartis, Eisai, Astellas Pharma, Regeneron, RAPT Therapeutics, Geovax Labs, Janssen, Summit Therapeutics Speakers' Bureau: Coherus Biosciences Research Funding (Inst.): Hookipa Biotech, EMD Serono, Purple Biotech, Bristol-Myers Squibb/Celgene, BeiGene, Abbvie, Astellas Pharma, Pfizer, Janux Therapeutics

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Host: Rick Grobbee Guest: Annemien van den Bosch Want to watch that extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2552 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson

In this episode, Donna and Tom sit down with Elena Polansky, Founder of Somerset Solutions Advisory Partners and former Chief Procurement Officer and Vice President of Global Sourcing & Procurement at BioMarin Pharmaceutical, to explore the evolution of procurement from a support function to a strategic value-engine. Elena shares insights from her 25-year career, including over 20 years at Pfizer where she delivered more than $1 billion in cumulative savings. She discusses navigating hidden costs in global sourcing, from geopolitical volatility to regulatory complexities, and the unique procurement challenges within life sciences. Elena also emphasizes the power of curiosity, asking smart questions, and staying open to feedback as essential traits for success in today's dynamic supply chain landscape. Takeaways: Procurement's transformation into a strategic business driver Managing hidden costs and risks in global pharmaceutical sourcing The role of innovation and technology in modern procurement The importance of curiosity and continuous learning Stay connected with CSCR on LinkedIn (Center for Supply Chain Research) and Instagram (@pennstatesupplychain), and be sure to follow us on Spotify, Apple Podcasts, or wherever you are tuning into Unpacked: Insights hosted by the Penn State Smeal Center for Supply Chain Research™. Thank you for joining us!  Visit our website: https://www.smeal.psu.edu/cscr  Guest Bio: Elena Polansky is a results-driven executive and strategic advisor with more than two decades of experience transforming procurement, operations, and organizational culture across global enterprises. As the Founder of Somerset Solutions Advisory Partners, she focuses on unlocking value through procurement transformation, supplier ecosystem optimization, and strategic advisory support. Her work centers on helping organizations evolve with clarity, confidence, and measurable impact. Before launching Somerset Solutions, Elena served as Chief Procurement Officer and Vice President of Global Sourcing & Procurement at BioMarin Pharmaceutical, where she established a centralized global sourcing function. Under her leadership, the team harmonized tools and processes, strengthened sourcing capabilities, and exceeded savings targets. Elena spent 20 years at Pfizer, advancing through multiple senior leadership roles in Global Sourcing and Global Supply. She delivered more than $1 billion in cumulative savings across direct and indirect categories and led the Internal Medicines External Supply organization, overseeing a global network of 50+ contract manufacturers producing 1,500+ SKUs. Her leadership ensured supply continuity, quality, and agility across diverse and highly regulated supply ecosystems. Elena began her career in consulting, leading strategy development, technology implementations, and change management initiatives for clients in the manufacturing and distribution sectors. At Andersen, she executed ERP implementations and software selection engagements; at Proxicom, she shaped digital strategy for a global bank and led the design of an internal knowledge management platform that improved collaboration and firm-wide efficiency. Elena is a proud Penn State alumna, holding a BS in Business Logistics and International Business from the Smeal College of Business. She resides in New Jersey with her husband—also a Penn State graduate—their two children, and their two dogs.

This week we chat with Jason Feifer! Jason is the Editor in Chief of Entrepreneur Magazine, where he's spent nearly a decade studying and telling the stories of the world's most successful entrepreneurs. He's also a startup advisor, keynote speaker, and a nonstop optimism machine.He's the author of the best-selling book Build For Tomorrow, host of the hit podcast Help Wanted with over one million monthly downloads, and the writer of the weekly newsletter One Thing Better, read by more than 70,000 leaders. LinkedIn has named him a Top Voice in Entrepreneurship.Beyond media, Jason is the cofounder of CPG Fast Track, Chief Content Officer for the business community Uncharted, and a trusted advisor to startups. He's delivered keynotes for global brands like Google, Microsoft, Pfizer, and Alibaba—helping teams turn adaptability into a competitive advantage.And above all, Jason is a husband and proud father of two, bringing heart and clarity to everything he builds.✨ This episode is presented by Brex.Brex: brex.com/trailblazerspodThis episode is supported by RocketReach, Gusto, OpenPhone & Athena.RocketReach: rocketreach.co/trailblazersGusto: gusto.com/trailblazersQuo: Quo.com/trailblazersAthena: athenago.me/Erica-WengerFollow Us!Jason Feifer: @heyfeifer@thetrailblazerspod: Instagram, YouTube, TikTokErica Wenger: @erica_wenger

Medical training is still stuck in the arcade era: expensive, basement-bound simulators and outdated software that rarely capture the real stakes of clinical decision-making. In this episode, host Alexandra Takei, Studio Director at Ruckus Games, sits down with Sam Glassenberg, founder of Level Ex (now part of Relevate Health), to unpack how game developers can modernize healthcare learning by truly embracing the craft of video game design, not “gamification” lipstick. The opportunity and the market here are much bigger than you might assume. Healthcare is a trillion-dollar industry in the US alone, and if you can create products that save the medical system money while also growing the $200B video game industry, that's a win-win. The conversation explores why even mediocre games outperform traditional training (the bar is shockingly low), and how live-ops principles let teams update clinical guidance fast. The pair also discusses who plays these games, and it turns out that it's not only doctors but “normal people” who have found these games on the app store. They go deep on design: mapping real clinical challenges to proven genres (diagnosis as reductive-reasoning puzzles, ventilators as rhythm games), and why domain experts often describe what's hard for residents, not what triggers adrenaline for experts, which is the source of “fun” in games. Finally, Sam breaks down the business: sponsored content by clients like Pfizer and Merck, free-to-play for doctors gameplay, and playable ads. We'd also like to thank Overwolf for making this episode possible! Whether you're a gamer, creator, or game studio, Overwolf is the ultimate destination for integrating UGC in games! You can check out all Overwolf has to offer at https://www.overwolf.com/.If you like the episode, please help others find us by leaving a 5-star rating or review! And if you have any comments, requests, or feedback shoot us a note at podcast@naavik.co. Watch the episode: YouTube ChannelFor more episodes and details: Podcast WebsiteFree newsletter: Naavik DigestFollow us: Twitter | LinkedIn | WebsiteSound design by Gavin Mc Cabe.

When leaders don't define decision guardrails early, decisions drift upward, risk feels unsafe, and teams stop building the muscle to decide for themselves.In this episode of Let's Talk, People, Emily sits down with Olesya Govorun, who leads organizational development and culture transformation at Pfizer, to unpack why ineffective decision-making is one of the most costly (and fixable) leadership challenges today.Drawing on her work at Pfizer, including efforts to empower expert-level decision-making during the rapid development and launch of the COVID-19 vaccine, Olesya shares what it actually takes to move decisions closer to the work without sacrificing alignment or trust.Together, they explore why decision rights often remain unclear, how over-involving leaders slows momentum, and what leaders can do to shift from being the final approver to building confident, capable decision-makers across their teams.Whether you're leading in a complex organization, navigating high-stakes change, or trying to speed up execution without losing rigor, this episode offers practical frameworks and mindset shifts to help you redesign how decisions get made and unlock better outcomes at every level.Timestamps: [00:16:40] Establishing Decision Guardrails Early – Olesya introduces the principle of Decision Guardrails - clarifying and agreeing upon which decisions can be fully owned, who gets to decide, and when a decision needs feedback or approval.[00:19:34] Decision-Making as a Learnable Skill – Emily and Olesya explore how leaders can reduce the fear and risk tied to decision-making by adopting a learner's mindset and providing the right supports like coaching, training, hands-on experience, and real-time feedback.[00:22:31] Making It Safe for People to Make Decisions – Emily and Olesya unpack how psychologically safe teams create norms around risk-taking, having disagreement, and challenging ideas (not people) to make better decisions faster.[00:26:11] Shifting the Role of the Leader from Decision Makers to Decision Builders – Olesya articulates that one of the most critical roles of leadership today is building others' confidence and capability to decide.Access the episode transcript.Join the Conversation: This year we're taking audience questions! Send in your toughest people management and leadership challenges, and we'll anonymize them and tackle them in an upcoming episode. Email Abigail on our Let's Talk, People team with your situation as a written note or voice memo to abigail@arosegroup.com.Connect with Emily Frieze-Kemeny on LinkedIn and Instagram or explore her work through AROSE Group's website.If you'd like to receive new episodes as they're...

On her first day as CFO at Greenphire, Sue Vestri sat in a conference room “learning all of the acronyms” of the clinical trial industry, she tells us. There were “many, many, many,” she recalls, and she listened to the sales team outside her door to understand how the product was positioned and why it mattered.That willingness to learn from the ground up defines her career. Earlier, a mentor warned her she would stagnate if she stayed in the safety of a large company. “You've got to go to grow,” he told her. She left for a 100-employee cloud software firm, a decision that launched a string of growth-company chapters, transactions, and ultimately multiple CFO seats.At Greenphire, she joined when the company had roughly 72 employees and “very low double digit revenue,” she tells us. Under private equity ownership, it expanded globally, shifted from clinical sites to big pharma customers, and supported the Pfizer clinical trial during COVID. Sue and her CEO conducted “20 or 30 presentations” during a remote exit process, she tells us.Today, as CFO of CRIO, she describes finance as embedded in the business—not “sitting behind a desk… producing financial statements.” Her filter for AI is deliberate: avoid the “shiny object” and invest in what is “truly transformational,” she explains. Whether evaluating predictive revenue indicators or AI tools, Sue's throughline remains the same—grow, but with discipline.

Ваш любимый канал «ВОТ ЭТО английский» — теперь в аудиоформате!Попробуйте и научитесь понимать английский на слух с удовольствием

Disclosures:Dr. Creech has disclosures of grant funding from NIH, CDC, Moderna, Pfizer and has been a consultant for Merck, Sanofi Paseur, TD. Cowen. Guidepoint Global, GSK, Delbiopharm, Dianthus, AstraZenecka and receives royalties from UpToDateWebsites:Philadelphia Children's Hospital Vaccine Education & ResourcesVUMC Children's Immunization GuideAAPRecommended Books:Anxious Generation: How The Great Rewiring of Childhood Is Causing an Epidemic of Mental Illness, Jonathan HaidtRighteous Mind: Why Good People Are Divided by Politics and Religion, Jonathan HaidtKey TakeawaysRSV prevention now includes both maternal vaccination during third trimester and monoclonal antibodies for infants, both showing 60-80% reduction in hospitalizationsHepatitis B vaccine is fundamentally a cancer prevention tool, and the birth dose is recommended at population level to prevent missed cases even when individual risk appears lowCocooning newborns through family immunization for influenza, pertussis, RSV, and measles is critical as community vaccination rates declineEffective vaccine conversations require avoiding shame and blame, expressing intellectual humility, asking "why" to understand concerns, and providing trusted resources rather than just educationThe future of vaccine development includes improved flu vaccines requiring less frequent administration, alternative delivery methods (intranasal, oral, microneedles), and advanced tools to understand rare adverse eventsWhile vaccine-preventable diseases like measles are increasing in pockets of under-vaccinated communities, maintaining high vaccination rates is essential to prevent widespread outbreaks of highly contagious diseasesParents face significant peer pressure around vaccine decisions, and healthcare providers should acknowledge this while modeling respectful dialogue with those who disagreeQuotable Moments"What is hepatitis B vaccine? It's a cancer prevention vaccine period. It prevents liver cancer. Why would I not want a cancer preventing vaccine?""An ounce of prevention is worth a pound of cure rather than knowing how to treat meningitis really effectively. Wouldn't it be great if we could prevent it all together?""I think we need to recognize that we probably want the same thing, except in extraordinarily weird situations. We both want the health of that child.""I recognize that there is still much to learn about these things, but here's where I land.""Vaccines and your baby's health, that's just more complicated than 140 characters.""Measles is the second most contagious virus on the planet behind smallpox, which is eradicated. So it's the first most...

“I do not believe we should be testing to test. We have to know, is this test going to change management and is it going to make a difference,” says pediatric allergist-immunologist Dr. Zachary Rubin. His knack for providing that sort of straightforward guidance explains why Dr. Rubin has become a trusted voice on allergies, asthma, and vaccines for his millions of followers on social media platforms. It's also why we couldn't ask for a better guide for our discussion on the rise in allergies, asthma, and immune-related conditions in children, and how families can navigate the quickly evolving science and rampant misinformation in the space. On this episode of Raise the Line, we also preview Dr. Rubin's new book, All About Allergies, in which he breaks down dozens of conditions and diseases, offering clear explanations and practical treatment options for families. Join host Lindsey Smith for this super informative conversation in which Dr. Rubin shares his thoughts on a wide range of topics including: What's behind the rise in allergic and immune-related conditions.Tips for managing misinformation, myths and misunderstandings. How digital platforms can be leveraged to strengthen public health.How to build back public trust in medicine.Mentioned in this episode:All About Allergies bookBench to Bedside PodcastInstagramTikTokYouTube Channel If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

The most impactful development of the past week that's gained the least amount of attention has been the rollout of TrumpRx. The program launched with 43 drugs (including high-profile ones like Ozempic, Wegovy, Zepbound, and fertility treatments) from companies like Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, and others offering Americans the lowest price available on these drugs anywhere in the world. 

Jeff Dornik joins The Jayne Carroll Show to explain why Democrats are willing to sacrifice Hillary Clinton and Bill Clinton in a calculated narrative operation designed to damage Donald Trump ahead of the midterms. He argues this strategy is rooted in Epstein exposure, selective prosecution, and political gaslighting, while calling out Pam Bondi for protecting Pfizer, blocking whistleblower Brooke Jackson, and refusing to prosecute deep state operatives. Dornik warns that truth no longer matters in Washington and that unless Republicans go on offense, fire Bondi, and expose corruption honestly, the midterms will be lost and accountability will never come.Follow Jeff Dornik on Pickax - https://pickax.com/jeffdornik Tune into The Jeff Dornik Show LIVE daily at 1pm ET on Rumble. Subscribe on Rumble and never miss a show. https://rumble.com/c/jeffdornik Big Tech is silencing truth while farming your data to feed the machine. That's why I built Pickax… a free speech platform that puts power back in your hands and your voice beyond their reach. Sign up today: https://pickax.com/?referralCode=y7wxvwq&refSource=copy

"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04

Incogni advertisementUse code “https://nordvpn.com/earthancients at the link below to get an exclusive 60% off an anual Incogni plan.Your URL is: https://incogni.com/earthancientsMichael J. Menard: Greater Than Gravity, How Childhood Trauma is Pulling Down HumanityWhat if America's #3 leading cause of death has been hiding in plain sight?In Greater Than Gravity, Michael Menard exposes a devastating truth that will shock the world: Childhood trauma is killing 889 Americans every day—more than accidents, strokes, and diabetes combined. Yet it doesn't appear on any official cause-of-death list because we've been counting the bodies wrong.When someone with severe childhood trauma dies of a "heart attack" at 55 instead of 75, we call it heart disease. When they overdose, it's addiction. When they take their own life, it's suicide. But strip away the medical terminology and you see the truth: these are trauma deaths, pure and simple."This is the largest threat to the well-being of humanity known today." —Dr. Glenn Schiraldi, world-renowned trauma expertAfter building a corporate empire and creating fourteen revolutionary patents, Menard made a discovery that stopped him cold. While writing his memoir about growing up with thirteen siblings, he realized their "tough childhood" was actually complex trauma. Its deadly fingerprints were everywhere—two brothers lost to addiction, his family stalked by depression, and invisible wounds that bled across generations.His engineer's mind couldn't let it go.What he uncovered will change everything: Childhood Trauma is the #1 cause of addiction, suicide and incarceration. 89% of teen suicide attempts trace to childhood trauma. 85-100% of addiction patients have trauma histories. 90% of prisoners carry childhood scars. The $14 trillion annual cost exceeds our entire defense budget. We've been treating symptoms while the real epidemic claims nearly 900 lives daily.But here's what no one saw coming: The very force pulling humanity down could become the force that lifts us up.Greater Than Gravity isn't just a book—it's the battle cry that breaks the silence on America's hidden killer. Through his foundation UACT, Menard presents the first comprehensive plan to end childhood trauma entirely. Not reduce it. Not manage it. END IT. The 889 daily deaths we could prevent. The lives we could heal. The future we could change.It all starts with opening this book.Labeled as "non college bound" he was placed in a trade school program. At the age of twenty-one Michael Menard joined Johnson & Johnson to operate the blueprint machine. Twenty-five years later he was named the company's first VP of engineering and an officer of the company with responsibilities in forty-four countries. Now labeled as "exemplary creator", he has received fourteen US and multiple international patents, including the inventions of infant disposable diapers with elastic legs and sanitary napkins with wings for women.As co-founder and president of The GenSight Group, a company helping corporations find a systematic approach to strategic choice and resource optimization, Michael has advised senior leadership at institutions such as Fedex, Westinghouse, Cisco, Glaxo, Pfizer, Coca-Cola, and the US Department of Energy. Michael has contributed to numerous professional publications including Harvard Management Update, Gartner Research, and The Journal of the American Management Association.https://www.michaeljmenard.com/aboutBecome a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

What’s Trending: A road rage incident involving a baseball bat and a knife, someone is allegedly stealing from the office market and lawmakers are considering banning sales of pets at pet stores. // Starbucks workers were required to return to the office and the Kraken canceled its in-house band for Bezos comments. // Actor Zachary Levi says Pfizer is a danger to the world.

The latest episode of Tin Foil Hat features Justin Leslie discussing his work on Pfizer's mRNA vaccine platform, why he became a whistleblower, and his views on true health, the terrain model, and virology. He shares insider perspectives on Project Veritas, Project Whistleblower, and investigations into alternative media figures, raising questions about transparency and controlled opposition. The episode also explores media manipulation, medical ethics, bodily autonomy, and alternative health models beyond Big Pharma. Please subscribe to the new Tin Foil Hat youtube channel:  https://www.youtube.com/@TinFoilHatYoutube Grab your copy of the 2nd issue of the Chaos Twins now and join the Army Of Chaos: https://bit.ly/415fDfY Check out Sam "DoomScrollin with Sam Tripoli and Midnight Mike" Every Tuesday At 4pm pst on Youtube, X Twitter, Rumble and Rokfin! Join the WolfPack at Wise Wolf Gold and Silver and start hedging your financial position by investing in precious metals now! Go to https://www.samtripoli.gold/ and use the promo code "TinFoil" and we thank Tony for supporting our show. CopyMyCrypto.com: The 'Copy my Crypto' membership site shows you the coins that the youtuber 'James McMahon' personally holds - and allows you to copy him. So if you'd like to join the 1300 members who copy James, then stop what you're doing and head over to: https://copymycrypto.com/tinfoilhat/ You'll not only find proof of everything I've said - but my listeners get full access for just $1 LiveLongerFormula.com: Check out https://www.livelongerformula.com/sam — Christian is a longevity author and functional health expert who helps you fix your gut, detox, boost testosterone, and sleep better so you can thrive, not just survive. Watch his free masterclass on the 7 Deadly Health Fads, and if it clicks, book a free Metabolic Function Assessment to get to the root of your health issues. Grab Tickets To Sam Tripoli's Live Shows At SamTripoli.com: Hollywood, CA: 2/10 Perryville, MD: 2/20 Pottstown, PA: 2/21 Las Vegas, NV: 2/28 Bakersfield, CA: 3/6 Yuma, AZ: 3/7 Hollywood, CA: 3/10 Batavia, IL: 3/26-3/28 Toronto, CA: 4/17-18 Dallas, TX: 4/24 Fort Worth, TX: 4/25 Albuquerque, NM: 6/12-6/13 Lawerence, KS: 9/17-9/19 Tulsa, OK: 10/9-10/10   Please check out Justin Leslie's internet:  Website: https://justintegrity.net Rumble: https://rumble.com/c/justintegrity Twitter: https://x.com/justintegrityy Instagram: https://www.instagram.com/justin.leslie3/ Youtube: https://www.youtube.com/@JustIntegrityNetwork   Please check out Sam Tripoli's internet: Linktree: https://linktr.ee/samtripoli Sam Tripoli's Stand Up Youtube Page: https://www.youtube.com/@SamTripoliComedy  Sam Tripoli's Comedy Instagram: https://www.instagram.com/samtripolicomedy/%20P Sam Tripoli's Podcast Clip Instagram: https://www.instagram.com/samtripolispodcastclips/   Please support our sponsors: ShipStation: Try ShipStation free for sixty days with Full access to all features, No credit card needed! Go to Ship Station dot com  and use code tinfoil for sixty  days for free! Sixty days gives you plenty of time to see exactly how much time and money you're saving on every shipment.That's Ship Station dot com code tinfoil. Ship Station dot com code tinfoil. QUO: Quo is the #1-rated business phone system on G2 with over 3,000 reviews, trusted by more than 90,000 businesses to stay connected and professional. Calls, texts, voicemails, transcripts, and contacts all live in one clean view, giving your team full context and faster communication. Make this the year no opportunity slips away. Try Quo for free and get 20% off your first six months at Quo dot com slash TINFOIL. That's Q-U-O dot com slash TINFOIL. Quo — no missed calls, no missed customers.